Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 5Breast 5Head & Neck 3Genitourinary 2Gastrointestinal 2Thoracic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 5Breast Neoplasms 4Uterine Cervical Neoplasms 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Neoplasms by Site 2Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Breast Diseases 2Salivary Gland Neoplasms 1Esophageal Squamous Cell Carcinoma 1

Interventions

pembrolizumab 30Nivolumab 10Cyclophosphamide 9fludarabine 7atezolizumab 7aldesleukin 5Paclitaxel 5Magnetic Resonance Spectroscopy 5Ipilimumab 5Carboplatin 5Biopsy 5cemiplimab 4Trastuzumab 4Interleukin-2 4Docetaxel 4Cisplatin 4spartalizumab 3durvalumab 3Specimen Handling 3Polymerase Chain Reaction 3Gene Expression Profiling 3Fulvestrant 3Fluorouracil 3tisotumab vedotin 2tislelizumab 2palbociclib 2fludarabine phosphate 2entinostat 2avelumab 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Fulvestrant × Head & Neck × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07109726 2026-05-22

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Terremoto Biosciences Inc.

Phase 1/2 Recruiting
205 enrolled
BreastGastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06993844 2026-05-06

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Ensem Therapeutics

Phase 1/2 Recruiting
233 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡